Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia

Lima, 2011, Cryptosporidiosis Yoder, 2010, Cryptosporidium surveillance and risk factors in the United States, Exp Parasitol, 124, 31, 10.1016/j.exppara.2009.09.020 Rossignol, 2010, Cryptosporidium and Giardia: treatment options and prospects for new drugs, Exp Parasitol, 124, 45, 10.1016/j.exppara.2009.07.005 Xiao, 2004, Cryptosporidium taxonomy: recent advances and implications for public health, Clin Microbiol Rev, 17, 72, 10.1128/CMR.17.1.72-97.2004 Mead, 2002, Cryptosporidiosis and the challenges of chemotherapy, Drug Resist Updat, 5, 47, 10.1016/S1368-7646(02)00011-0 El-Hamshary, 2008, Comparison of polymerase chain reaction, immunochromatographic assay and staining techniques in diagnosis of cryptosporidiosis, Parasitologists United Journal, 2, 77 Heyworth, 1996, Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis, Gastroenterol Clin North Am, 25, 691, 10.1016/S0889-8553(05)70269-7 Griffiths, 1998, Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment, and diagnosis Miller, 2007, Chemically and genetically immunocompromised mice are not more susceptible than immunocompetent mice to infection with Cryptosporidium muris, Vet Parasitol, 143, 99, 10.1016/j.vetpar.2006.08.012 Okhuysen, 2002, Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice, J Infect Dis, 185, 1320, 10.1086/340132 Toketo, 2006, Mouse models of gastrointestinal tumors, Cancer Sci, 97, 355, 10.1111/j.1349-7006.2006.00190.x Lacroix, 2001, Cryptosporidium parvum-specific mucosal immune response in C57BL/6 neonatal and gamma interferon-deficient mice: role of tumor necrosis factor alpha in protection, Infect Immun, 69, 1635, 10.1128/IAI.69.3.1635-1642.2001 Certad, 2007, Cryptosporidium parvum, a potential cause of colic adenocarcinoma, Infect Agent Cancer, 2, 22, 10.1186/1750-9378-2-22 Bartkova, 1994, The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas, Int J Cancer, 58, 568, 10.1002/ijc.2910580420 Bartkova, 1995, Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis, Oncogene, 10, 775 Arber, 1996, Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis, Gastroenterology, 110, 669, 10.1053/gast.1996.v110.pm8608874 Lukas, 1994, Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines, Oncogene, 9, 707 Ridley, 1956, The value of formol–ether concentration of faecal cysts and ova, J Clin Pathol, 9, 74, 10.1136/jcp.9.1.74 Henriksen, 1981, Staining of cryptosporidia by a modified Ziehl–Neelsen technique, Acta Vet Scand, 22, 594, 10.1186/BF03548684 Rehg, 1988, Characterization of a dexamethasone-treated rat model of cryptosporidial infection, J Infect Dis, 158, 1406, 10.1093/infdis/158.6.1406 Anderson, 1985, Moist heat inactivation of Cryptosporidium sp, Am J Public Health, 75, 1433, 10.2105/AJPH.75.12.1433 Xiao, 1999, Genetic diversity within Cryptosporidium parvum and related Cryptosporidium species, Appl Environ Microbiol, 65, 3386, 10.1128/AEM.65.8.3386-3391.1999 Alves, 2003, Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal, J Clin Microbiol, 41, 2744, 10.1128/JCM.41.6.2744-2747.2003 Amer, 2010, Cryptosporidium genotypes and subtypes in dairy calves in Egypt, Vet Parasitol, 169, 382, 10.1016/j.vetpar.2010.01.017 Certad, 2012, Fulminant cryptosporidiosis after near-drowning: a human Cryptosporidium parvum strain implicated in invasive gastrointestinal adenocarcinoma and cholangiocarcinoma in an experimental model, Appl Environ Microbiol, 78, 1746, 10.1128/AEM.06457-11 Current, 1983, Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission, N Engl J Med, 308, 1252, 10.1056/NEJM198305263082102 Campbell, 1983, Demonstration of serum antibodies to Cryptosporidium sp. in normal and immunodeficient humans with confirmed infections, J Clin Microbiol, 18, 165, 10.1128/JCM.18.1.165-169.1983 Reese, 1982, Cryptosporidiosis of man and calf: a case report and results of experimental infections in mice and rats, Am J Trop Med Hyg, 31, 226, 10.4269/ajtmh.1982.31.226 Zierdt, 1984, Concentration and identification of Cryptosporidium sp. by use of a parasite concentrator, J Clin Microbiol, 20, 860, 10.1128/JCM.20.5.860-861.1984 Moon, 1982, Experimental fecal transmission of human cryptosporidia to pigs, and attempted treatment with an ornithine decarboxylase inhibitor, Vet Pathol, 19, 700, 10.1177/030098588201900615 Suresh, 1996, Comparative evaluation of several techniques for purification of Cryptosporidium parvum oocysts from rat feces, J Clin Microbiol, 34, 38, 10.1128/JCM.34.1.38-40.1996 Paget, 1964, Evaluation of drug activities Healey, 1995, Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum, J Parasitol, 81, 114, 10.2307/3284020 Hamilton, 2000, Carcinoma of the colon and rectum Milhalov, 2002, Gastrointestinal system Cooper, 2004, Intestinal neoplasms Abubakar, 2007, Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis, Br J Clin Pharmacol, 63, 387, 10.1111/j.1365-2125.2007.02873.x Riggs, 2002, Recent advances in cryptosporidiosis: the immune response, Microbes Infect, 4, 1067, 10.1016/S1286-4579(02)01631-3 Singh, 2005, Kinetics of Cryptosporidium parvum-specific cytokine responses in healing and nonhealing murine models of C. parvum infection, Parasitol Res, 97, 309, 10.1007/s00436-005-1436-1 Lacroix-Lamandé, 2002, Role of gamma interferon in chemokine expression in the ileum of mice and in a murine intestinal epithelial cell line after Cryptosporidium parvum infection, Infect Immun, 70, 2090, 10.1128/IAI.70.4.2090-2099.2002 Gookin, 2006, NF-κB-mediated expression of iNOS promotes epithelial defense against infection by Cryptosporidium parvum in neonatal piglets, Am J Physiol Gastrointest Liver Physiol, 290, G164, 10.1152/ajpgi.00460.2004 Franchimont, 2004, Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies, Ann N Y Acad Sci, 1024, 124, 10.1196/annals.1321.009 Stojadinovic, 2007, Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation, J Biol Chem, 282, 4021, 10.1074/jbc.M606262200 Matsui, 2001, Infectivity and oocyst excretion patterns of Cryptosporidium muris in slightly infected mice, J Vet Med Sci, 63, 319, 10.1292/jvms.63.319 Kapel, 1997, Cryptosporidiosis-induced impairment of ion transport and Na+-glucose absorption in adult immunocompromised mice, J Infect Dis, 176, 834, 10.1086/517316 Chai, 1999, Role of intraepithelial lymphocytes in mucosal immune responses of mice experimentally infected with Cryptosporidium parvum, J Parasitol, 85, 234, 10.2307/3285625 McDonald, 1992, Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice, Infect Immun, 60, 3325, 10.1128/IAI.60.8.3325-3331.1992 Tarazona, 1998, Cryptosporidium parvum infection in experimentally infected mice: infection dynamics and effect of immunosuppression, Folia Parasitol (Praha), 45, 101 Ahmet, 2003, Immune deficiency and cryptosporidiosis in rats, Turk J Vet Anim Sci, 27, 1187 Leitch, 1999, Reactive nitrogen and oxygen species ameliorate experimental cryptosporidiosis in the neonatal BALB/c mouse model, Infect Immun, 67, 5885, 10.1128/IAI.67.11.5885-5891.1999 Verdon, 1998, Cryptosporidium parvum biliary tract infection in adult immunocompetent and immunosuppressed mice, J Med Microbiol, 47, 71, 10.1099/00222615-47-1-71 Certad, 2010, Fulminant cryptosporidiosis associated with digestive adenocarcinoma in SCID mice infected with Cryptosporidium parvum TUM1 strain, Int J Parasitol, 40, 1469, 10.1016/j.ijpara.2010.07.007 Sulzyc-Bielicka, 2007, Cryptosporidiosis in patients with colorectal cancer, J Parasitol, 93, 722, 10.1645/GE-1025R1.1 Bartkova, 2001, Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon, Gastroenterology, 120, 1680, 10.1053/gast.2001.24880 Zhang, 1997, Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients, Cancer Res, 57, 169 Takeuchi, 2008, Cooperative role of macrophages and neutrophils in host antiprotozoan resistance in mice acutely infected with Cryptosporidium parvum, Infect Immun, 76, 3657, 10.1128/IAI.00112-08 Kasper, 2001, Ups and downs of mucosal cellular immunity against protozoan parasites, Infect Immun, 69, 1, 10.1128/IAI.69.1.1-8.2001 Lean, 2003, Interleukin-4 and transforming growth factor beta have opposing regulatory effects on gamma interferon-mediated inhibition of Cryptosporidium parvum reproduction, Infect Immun, 71, 4580, 10.1128/IAI.71.8.4580-4585.2003 Kayser, 2001, A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications, Int J Pharm, 214, 83, 10.1016/S0378-5173(00)00640-2 Adagu, 2002, In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis, J Antimicrob Chemother, 49, 103, 10.1093/jac/49.1.103 Bailey, 2004, Nitazoxanide treatment for giardiasis and cryptosporidiosis in children, Ann Pharmacother, 38, 634, 10.1345/aph.1D451 Fox, 2005, Nitazoxanide: a new thiazolide antiparasitic agent, Clin Infect Dis, 40, 1173, 10.1086/428839 Gargala, 2008, Drug treatment and novel drug target against Cryptosporidium, Parasite, 15, 275, 10.1051/parasite/2008153275 Rossignol, 2001, Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide, J Infect Dis, 184, 103, 10.1086/321008 Amadi, 2009, High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial, BMC Infect Dis, 9, 195, 10.1186/1471-2334-9-195